Chances of DCIS Recurrence
Ductal carcinoma in situ, or DCIS, is the most common type of non-invasive breast cancer. Newly diagnosed patient my wonder what the risk of DCIS recurrence is after treatment. Dr. Rick Baehner goes over what typical recurrence rates are for typical patients.
Genomic Health is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. The company's lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).
SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS
http://www.youtube.com/user/drjayharness
VISIT BREASTCANCERANSWERS.com FOR INFORMATIVE VIDEOS
http://www.breastcanceranswers.....com/video-categorie
SUBMIT A QUESTION
http://www.breastcanceranswers.com/ask
DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR
http://www.breastcanceranswers.....com/what-breast-can
CONNECT WITH US!
Google+: http://bit.ly/16nhEnr
Facebook: https://www.facebook.com/BreastCancerAnswers
Twitter: https://twitter.com/BreastCancerDr
______
Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
-
Category
No comments found